Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Keratosis, Actinic 12Head and Neck Neoplasms 3Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Exanthema 2Colorectal Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Warts 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Radiodermatitis 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Nivolumab 2Gemcitabine 2Cisplatin 2B701 protein, Human herpesvirus 6 2valrubicin 1tislelizumab 1relatlimab 1enzalutamide 1enfortumab vedotin 1durvalumab 1Water 1Urinary Diversion 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Multiparametric Magnetic Resonance Imaging 1Immunonutrition Diet 1Immune Checkpoint Inhibitors 1Gels 1Fluorouracil 1Docetaxel 1Cystoscopy 1Cystectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Diseases × Gels × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡